Abstract | OBJECTIVE: There is still no consensus regarding the treatment of empyema in children. Intrapleural combination of tissue plasminogen activator and dornase alfa is a promising treatment for empyema in adults. The aim of this pilot study was to determine whether this combination is safe and successful in pediatric empyema. METHODS: RESULTS: Ten consecutive children were included (4 boys, aged 3.2 (1.3-15.0) years old). No serious adverse events were seen. One child developed urticaria but additional intervention or cessation of the trial was not needed. There was no bleeding or mortality and no additional procedures were performed. The median hospital stay after intervention was 7.5 days. CONCLUSIONS:
|
Authors | Monique A Slaats, Jozef De Dooy, Kim Van Hoorenbeeck, Paul E Y Van Schil, Stijn L Verhulst, Jeroen M H Hendriks |
Journal | Acta chirurgica Belgica
(Acta Chir Belg)
Vol. 121
Issue 3
Pg. 184-188
(Jun 2021)
ISSN: 0001-5458 [Print] England |
PMID | 31750793
(Publication Type: Journal Article)
|
Chemical References |
- Fibrinolytic Agents
- Recombinant Proteins
- Deoxyribonuclease I
- dornase alfa
- Tissue Plasminogen Activator
|
Topics |
- Adolescent
- Child
- Child, Preschool
- Deoxyribonuclease I
- Empyema, Pleural
(drug therapy)
- Female
- Fibrinolytic Agents
(therapeutic use)
- Humans
- Infant
- Male
- Pilot Projects
- Recombinant Proteins
- Tissue Plasminogen Activator
|